Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical trial NCT02518555 · COMPLETED
Trial details
- NCT number
- NCT02518555
- Sponsor
- Jennifer Woyach
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-12
- Primary completion
- 2025-12-15
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.